THE EFFECT OF BROMOCRIPTINE ON THE LEVELS OF ALKALINE PHOSPHATASE AND LIVER OF IMMATURE MALE RATS
Downloads
Objectives: The purpose of this investigation was to ascertain how bromocriptine (BRO) affected the livers of young male rats. Method: On the first day of experiments, the first group of five immature male rats (16 days old) weighing 25–30g was slaughtered. The remaining rats were divided into four groups, each consisting of 10 animals. The 3rd and 4th groups received BRO (IP) at 3 and 6 mg/kg BW, respectively, for two periods (9 days and 27 days), whereas the second group acted as the control and received the vehicle (IP). For the recovery trial, five rats from each group were kept for a month without receiving any therapy. Results: When compared to the control group, BRO therapy resulted in: A) a substantial loss in body the weight, B) significant rise in liver weight, and C) a significant increase in blood levels of phosphatase-alkaline in immature albino rats of both treated the groups. Novelty: The current investigation leads us to the conclusion that, even though BRO had an impact on the liver of young male rats, the effects of BRO may be recovered after a month of no treatment.
J. D. L. Van Weenen, E. T. Parlevliet, P. Maechler, et al., "The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells," Biochemical Pharmacology, vol. 79, pp. 1827–1836, 2010.
R. A. DeFronzo, "Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes," Diabetes Care, vol. 34, pp. 789–794, 2011.
A. De Bellis, et al., "Bromocriptine in hyperprolactinemia: updated clinical practice," Endocrine, vol. 65, no. 3, pp. 514–521, 2019.
S. Melmed, et al., "Prolactinomas: current management and future perspectives," Lancet Diabetes Endocrinol., vol. 8, no. 12, pp. 898–908, 2020.
M. P. Gillam, et al., "Advances in dopamine agonist therapy for endocrine disorders," Nat. Rev. Endocrinol., vol. 16, no. 6, pp. 345–359, 2020.
A. K. Elshorbagy, et al., "Bromocriptine and hepatic lipid metabolism: insights from rodent models," Metabolism, vol. 120, p. 154780, 2021.
E. S. Björnsson, et al., "Drug-induced liver injury: recent advances in diagnosis and risk assessment," J. Hepatol., vol. 77, no. 1, pp. 110–125, 2022.
M. Clayton, "Hepatic encephalopathy: causes and health-related burden," Br. J. Nurs., vol. 27, pp. S4–S6, 2018.
W. Cash, P. McConville, E. McDermott, P. McCormick, M. Callender, and N. McDougall, "Current concepts in the assessment and treatment of hepatic encephalopathy," QJM, vol. 103, pp. 9–16, 2010.
A. T. Blei, "Diagnosis and treatment of hepatic encephalopathy," Best Pract. Res. Clin. Gastroenterol., vol. 14, pp. 959–974, 2000.
B. Als-Nielsen, L. L. Gluud, and C. Gluud, "Dopaminergic agonists for hepatic encephalopathy," Cochrane Database Syst. Rev., 2004.
K. Weissenborn, G. Berding, and H. Köstler, "Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy," Metab. Brain Dis., vol. 15, pp. 173–178, 2000.
P. J. Schwartz, "Regulation of Central Dopamine-2 Receptor Sensitivity by a Proportional Control Thermostat in Humans," Psychiatry Res., vol. 127, no. 1-2, pp. 19–26, 2004.
M. O. Thorner, E. Fluckiger, and D. B. Calne, "Bromocriptine: A Clinical and Pharmacological Review," Raven Press, New York, 1980, pp. 143–152.
I. Lancranjan, "The endocrine profile of bromocriptine: its application in endocrine diseases," J. Neural Transm., vol. 51, pp. 61–82, 1981.
J. E. Ahlskog, "Treatment of Parkinson disease from theory to practice," Postgrad. Med., vol. 95, pp. 52–54, 1994.
N. Ogawa, "Early introduction of dopamine agonists in the long-term treatment of Parkinson disease," Neurology, vol. 51, pp. 13–20, 1998.
S. Mahjoub and J. Masrour Roudsari, "Quantification of liver alkaline phosphatase isoenzyme activity using heat inactivation and phenylalanine inhibition techniques: Comparison of two methods," World Appl. Sci. J., vol. 17, no. 8, pp. 941–946, 2012.
P. Garnero and P. D. Delmas, "Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease," J. Clin. Endocrinol. Metab., vol. 77, no. 4, pp. 1046–1049, 1993.
R. P. Hof and A. Hof, "Effects of bromocriptine on the heart and peripheral circulation of anesthetized cats," J. Cardiovasc. Pharmacol., vol. 6, pp. 68–75, 1984.
A. M. Ageel, K. E. Tahir, and A. Abu-Jayyab, "Influence of bromocriptine on free amino acids in the kidneys and heart in rats," Biochem. Pharmacol., vol. 36, pp. 4293–4295, 1987.
J. Roquebert, A. Moran, P. Demichel, and M. F. Sauvage, "Pharmacological characterization of dopamine receptors in parasympathetic innervation of rat heart," Eur. J. Pharmacol., vol. 200, pp. 59–63, 1991.
H. P. Schobel, R. E. Schmieder, S. Hartmann, H. Schachinger, and F. C. Luft, "Effects of bromocriptine on cardiovascular regulation in healthy humans," Hypertension, vol. 25, pp. 1075–1082, 1995.
H. G. Klemcke, F. Blecha, and J. A. Nienaber, "Pituitary–adrenocortical and lymphocyte responses to bromocriptine-induced hypoprolactinemia, adrenocorticotropic hormone and restraint in swine," Comp. Biochem. Physiol. A., vol. 195, pp. 100–108, 1990.
M. H. A. Ameen, M. Bhagya, and H. N. Yajurvedi, "Effects of bromocriptine on ovarian follicular development in pre-pubertal rats," Int. J. Appl. Environ. Sci., vol. 6, pp. 1–10, 2011.
H. Green and J. Spencer, Drugs with possible ocular side-effects, Hatton, London, 1966.
N. Mehta, L. A. Ozick, and E. Gbadehan, "Drug-induced hepatotoxicity," 2014. [Online]. Available: http://emedicine.medscape.com/article/169814.
Y. O. Adejoke, J. O. Olakunle, F. Adewale, T. Ojo, S. Asolo, and O. Aisida, "Evidence of liver and kidney injuries attributable to oral bromocriptine methanesulfonate in mice," IOSR-JPBS, vol. 9, no. 2, pp. 55–61, 2014.
N. L. Liberato, M. Poli, P. Bollati, F. Chiofalo, and M. Filipponi, "Bromocriptine-induced acute hepatitis," Lancet, vol. 340, no. 8825, pp. 969–970, 1992.
E. S. Bjornsson and J. H. Hoofnagle, "Categorization of drugs implicated in causing liver injury: critical assessment based on published case report," Hepatology, vol. 63, no. 2, pp. 590–603, 2016.
R. A. Zager, "Pathogenetic mechanisms in nephrotoxic acute renal failure," Semin. Nephrol., vol. 17, pp. 3–14, 1997.
Copyright (c) 2025 Adhwaa Hameed Jaber
This work is licensed under a Creative Commons Attribution 4.0 International License.
